Cellzome Using Proteome Sciences' Mass Tag Tech for Proteomics Research | GenomeWeb
NEW YORK (GenomeWeb News) – Proteome Sciences will supply its tandem mass tag — or TMT — technology to German drug discovery company Cellzome, Proteome Sciences announced today.
 
Cellzome was an early beta test site for Proteome Sciences’ TMTsixplex, which allows up to six samples to be labeled, mixed, and subsequently identified. Now, Cellzome plans to apply the TMTsixplex technology to its own proteomics platform approach for analyzing protein-drug and protein-protein interactions.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.